Attached files
| file | filename |
|---|---|
| EX-31.1 - SECTION 302 CEO CERTIFICATION - Inhibitor Therapeutics, Inc. | d255474dex311.htm |
| EX-31.2 - SECTION 302 CFO CERTIFICATION - Inhibitor Therapeutics, Inc. | d255474dex312.htm |
| 10-Q - FORM 10-Q - Inhibitor Therapeutics, Inc. | d255474d10q.htm |
| EX-32.2 - SECTION 906 CFO CERTIFICATION - Inhibitor Therapeutics, Inc. | d255474dex322.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Commonwealth Biotechnologies, Inc. (the “Company”) on Form 10-Q for the quarter ending September 30, 2011 as filed with the Securities and Exchange Commission on , 2011 (the “Report”), I, Richard J. Freer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| November 14, 2011 | /s/ Richard J. Freer, Ph.D. | |||
| Richard J. Freer, Ph.D | ||||
| Chief Executive Officer |